Share on StockTwits

Research analysts at Aegis assumed coverage on shares of Akers Biosciences (LON:AKR) in a report released on Monday. The firm set a “buy” rating on the stock.

Separately, analysts at Daniel Stewart & Co reiterated a “buy” rating on shares of Akers Biosciences in a research note on Wednesday, May 7th.

Shares of Akers Biosciences (LON:AKR) traded down 4.59% during mid-day trading on Monday, hitting GBX 260.00. The stock had a trading volume of 650 shares. Akers Biosciences has a 52 week low of GBX 156.00 and a 52 week high of GBX 325.00. The stock’s 50-day moving average is GBX 274.2 and its 200-day moving average is GBX 357.4.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.